SEC Form 4 · accession 0001127602-17-025434
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Martine A Rothblatt
Officer — Chairman & CEO · Director
Period of report
Aug 10, 2017
Accepted (ET)
Aug 11, 2017 · 8:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 10, 2017 | M | 2,176 | $30.75 | A | 3,245 | D | |
| Common StockF2 | Aug 10, 2017 | M | 930 | $30.75 | A | 668,733 | I | By Trusts |
| Common StockF3 | Aug 10, 2017 | S | 2,176 | $127.1078 | D | 1,069 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $30.75 | Aug 10, 2017 | M | 2,176 | D | Dec 26, 2009 | Dec 31, 2017 | Common Stock | 2,176 | 33,896 | D |
| Stock OptionsF2 | $30.75 | Aug 10, 2017 | M | 930 | D | Dec 26, 2009 | Dec 31, 2017 | Common Stock | 930 | 32,966 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. The transaction was structured as a broker-assisted cashless exercise, such that the number of shares sold was limited to a sufficient number to cover the exercise price of the options and anticipated taxes. The remaining shares are held by a trust beneficially owned by the reporting person.
- F2Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- F3This transaction was executed in multiple trades at prices ranging from $126.65 to $127.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.